AU2009244805B2 - Oral administration of peripherally-acting opioid antagonists - Google Patents

Oral administration of peripherally-acting opioid antagonists Download PDF

Info

Publication number
AU2009244805B2
AU2009244805B2 AU2009244805A AU2009244805A AU2009244805B2 AU 2009244805 B2 AU2009244805 B2 AU 2009244805B2 AU 2009244805 A AU2009244805 A AU 2009244805A AU 2009244805 A AU2009244805 A AU 2009244805A AU 2009244805 B2 AU2009244805 B2 AU 2009244805B2
Authority
AU
Australia
Prior art keywords
opioid
opioid antagonist
antagonist
medicament
side effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009244805A
Other languages
English (en)
Other versions
AU2009244805A1 (en
Inventor
Kevin J. Brodbeck
Alan R. Kugler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of AU2009244805A1 publication Critical patent/AU2009244805A1/en
Application granted granted Critical
Publication of AU2009244805B2 publication Critical patent/AU2009244805B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009244805A 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists Active AU2009244805B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
US61/126,868 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (2)

Publication Number Publication Date
AU2009244805A1 AU2009244805A1 (en) 2009-11-12
AU2009244805B2 true AU2009244805B2 (en) 2013-01-10

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009244805A Active AU2009244805B2 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Country Status (15)

Country Link
US (1) US20110160239A1 (https=)
EP (1) EP2300009A1 (https=)
JP (1) JP2011519930A (https=)
KR (1) KR20110004425A (https=)
CN (1) CN102014907A (https=)
AU (1) AU2009244805B2 (https=)
BR (1) BRPI0912219A2 (https=)
CA (1) CA2723685C (https=)
EA (1) EA201001643A1 (https=)
IL (1) IL208794A0 (https=)
MX (1) MX2010011727A (https=)
MY (1) MY156913A (https=)
NZ (1) NZ589733A (https=)
WO (1) WO2009137086A1 (https=)
ZA (1) ZA201007531B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
UA123856C2 (uk) * 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
AU2011307608B8 (en) * 2010-09-30 2015-08-27 Grünenthal GmbH Crystalline naloxol-PEG conjugate
KR20140107540A (ko) * 2011-12-19 2014-09-04 샐릭스 파마슈티컬스 리미티드 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules
AU2007317788A1 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
KR101421747B1 (ko) * 2006-04-21 2014-07-30 넥타르 테라퓨틱스 모르피논의 입체선택적 환원

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules
AU2007317788A1 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELDON, M.A. et al, NEKTAR, Poster 27, 30 September 2007 *
MULLER-LISSNER, S. et al, European Journal of Pain, 2007, vol. 11, no. S1, page S82 *
NEUMANN, T.A. et al, NEKTAR, Poster 27, 30 September 2007 *
PAULSON, D. et al, The Journal of Pain, 2004, vol. 5, no. 3, page 57 *
WEBSTER, L. et al, The Journal of Pain, 2006, vol. 7, no. 4, page S41 *

Also Published As

Publication number Publication date
CA2723685A1 (en) 2009-11-12
MY156913A (en) 2016-04-15
EP2300009A1 (en) 2011-03-30
BRPI0912219A2 (pt) 2015-10-06
MX2010011727A (es) 2010-11-30
EA201001643A1 (ru) 2011-06-30
AU2009244805A1 (en) 2009-11-12
ZA201007531B (en) 2012-03-28
IL208794A0 (en) 2010-12-30
WO2009137086A1 (en) 2009-11-12
US20110160239A1 (en) 2011-06-30
NZ589733A (en) 2012-07-27
CA2723685C (en) 2016-09-27
CN102014907A (zh) 2011-04-13
KR20110004425A (ko) 2011-01-13
JP2011519930A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
AU2009244805B2 (en) Oral administration of peripherally-acting opioid antagonists
JP6226916B2 (ja) 医薬組成物
KR101545874B1 (ko) 난용성 약물의 전달을 위한 입상 조성물
EP1928438B1 (en) Use of ibudilast for treating drug addictions
CN106413717A (zh) 药物组合物
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
NZ210442A (en) Buprenorphine/naloxone composition
EP3148512A1 (en) Multiparticles safeguarded against ethanolic dose-dumping
AU2008220573A1 (en) Improved medicinal compositions comprising buprenorphine and naloxone
WO2017066488A1 (en) Treating pain using a composition comprising an opioid and an antiemetic
EP0514023B1 (en) Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
WO2017120468A1 (en) Therapeutic use of nalbuphine without aquaretic effects
HK1210959A1 (en) Use of opioid receptor antagonist for gastrointestinal tract disorders
US10016413B2 (en) Combination dopamine antagonist and opiate receptor antagonist treatment of addictive behavior
WO2019023368A1 (en) FORMULATIONS OF ORAL TABLETS
HK1176006A (en) Improved medicinal composition comprising buprenorphine and naltrexone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)